We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Active surveillance versus enzalutamide for low‐risk prostate cancer – was it really a trial we needed?
- Authors
Williams, Isabella S.C.; Perera, Sachin; Murphy, Declan G.; Corcoran, Niall M.; Bolton, Damien M.; Lawrentschuk, Nathan
- Abstract
Abbreviations AS active surveillance NCCN National Comprehensive Cancer Network The management of low-risk prostate cancer in North America has recently seen some unexpected, surprising, and somewhat perplexing occurrences. Examples include recent imaging trials using prostate-specific membrane antigen positron emission tomography-CT to better target and provide more informed initial biopsy as found in the PRIMARY trial [4], or CONFIRM trial (Australian New Zealand Clinical Trials Registry [ACTRN]12621001648819 at https://www.anzctr.org.au) aiming to better select men for AS prior to confirmatory biopsy. This trial concluded that 'enzalutamide monotherapy was well-tolerated and demonstrated a significant treatment response in patients with low-risk or intermediate-risk localized prostate cancer', and that 'enzalutamide may provide an alternative treatment option for patients undergoing AS'.
- Subjects
PROSTATE cancer; WATCHFUL waiting; POSITRON emission tomography computed tomography
- Publication
BJU International, 2022, Vol 130, Issue 5, p580
- ISSN
1464-4096
- Publication type
Article
- DOI
10.1111/bju.15860